scholarly journals A Meta-Analysis Study on Alzheimer’s Disease

To gather and assess information on Alzheimer’s disease and its treatment from published studies to depict the overall treatment effect. The metaphysical findings appear to indicate that Alzheimer’s disease has multiple causes. There have been reports of patients reporting different symptoms or causing different symptoms. Treatments and preventative measures, on the other hand, have historically been difficult to implement. There has been no clear evidence as to which drug or treatment will clearly reduce the severity of this disease until now. Scientists have created drugs and treatments that can aid in the prevention and treatment of patients who have recently been diagnosed with the disease. As a result, there is a good chance that the treatment will improve and eventually be able to fully cure Alzheimer’s patients. Over the last two decades, enormous progress has been made in understanding Alzheimer’s disease, including its diagnosis, treatment pattern, epidemiology, and economic impact. Alzheimer’s disease is one of the most incapacitating old-age diseases. Thanks to a thorough understanding of the disease’s natural history, we were able to develop appropriate trial designs and outcomes for the various stages of Alzheimer’s disease. Alzheimer’s disease treatment guidelines must be constantly updated to reflect new evidence in order to benefit patients and caregivers in the long run. As the population ages, the availability of new treatments for Alzheimer’s disease management, as well as changes in the health-care system, will necessitate the integration of existing knowledge in order to better meet the needs of Alzheimer’s patients and their families.

Author(s):  
Faraz Ahmad ◽  
Shafiul Haque ◽  
Vishal Chavda ◽  
Ghulam Md Ashraf

: The current meta-analysis of the cohort review was designed to elucidate the progress made in neuroproteomics of the synaptosome. The association of the comprehensive synaptic proteome and its link to physiological or pathological settings is rapidly mounting. Chemical synapses in the brain are focal hot spots for interneuronal signaling, signal transduction, and plasticity. Structurally, synapses comprise axon termini or the presynapse (vesicles filled with neurotransmitters that function as molecular signals), synaptic clefts (extracellular matrix and adhesion molecules), and post-synaptic density or PSD (with receptors for neurotransmitters that rely upon the chemical signaling). The pre- and post-synaptic clefts are responsible for mediating and regulating neurotransmitter release Their receptor binding and perception rely on chemical signals. Moreover, short- and long-term structural and functional alterations that are necessary for the optimal higher-order brain functions are also mainly dependent on the protein dynamics at the synapses. Not surprisingly, disruptions in synaptic physiology are considered as the major pathogenic mechanisms underlying the progression of several neurodegenerative disorders, including Alzheimer's disease. This review briefly discusses the subcellular fractionation protocols and the related biochemical approaches for the isolation of synaptic compartments. Besides, it discusses the progress made in understanding the pathological alterations in the synaptic proteome in neurodegenerative disorders, particularly focussing on Alzheimer's disease dementia.


2009 ◽  
Vol 5 (4S_Part_15) ◽  
pp. P457-P458 ◽  
Author(s):  
Henry J. Riordan ◽  
Neal Cutler ◽  
Farzin Irani ◽  
Paul J. Moberg

Author(s):  
Roja Rahimi ◽  
Shekoufeh Nikfar ◽  
Masoud Sadeghi ◽  
Mohammad Abdollahi ◽  
Reza Heidary Moghaddam ◽  
...  

Background: It has been found that there is a link between hypertension and elevated risk of Alzheimer’s disease (AD). Herein, a meta-analysis based on randomized clinical trials (RCTs) was used to assess the effect of antihypertensive drugs on cognition and behavioral symptoms of AD patients. Method: The three databases – PubMed/Medline, Scopus, and Cochrane Library- were searched up to March 2020. The quality of the studies included in the meta-analysis was evaluated by the Jadad score. Clinical Global Impression of Change (CGIC) included in two studies, Mini-Mental State Examination (MMSE) included in three studies, and Neuropsychiatric Inventory (NPI) in three studies were the main outcomes in this systematic review. Results: Out of 1506 studies retrieved in the databases, 5 RCTs included and analyzed in the meta-analysis. The pooled mean differences of CGIC, MMSE, and NPI in patients with AD receiving antihypertensive drugs compared to placebo was -1.76 with (95% CI = -2.66 to -0.86; P=0.0001), 0.74 (95% CI = 0.20 to 1.28; P= 0.007), and -9.49 (95% CI = -19.76 to 0.79; P = 0.07), respectively. Conclusion: The findings of the present meta-analysis show that antihypertensive drugs may improve cognition and behavioral symptoms of patients with AD. However, more well-designed RCTs with similar drugs are needed to achieve more conclusive results.


2018 ◽  
Vol 15 (7) ◽  
pp. 610-617 ◽  
Author(s):  
Huifeng Zhang ◽  
Dan Liu ◽  
Huanhuan Huang ◽  
Yujia Zhao ◽  
Hui Zhou

Background: β-amyloid (Aβ) accumulates abnormally to senile plaque which is the initiator of Alzheimer's disease (AD). As one of the Aβ-degrading enzymes, Insulin-degrading enzyme (IDE) remains controversial for its protein level and activity in Alzheimer's brain. Methods: The electronic databases PubMed, EMBASE, The Cochrane Library, OVID and Sinomed were systemically searched up to Sep. 20th, 2017. And the published case-control or cohort studies were retrieved to perform the meta-analysis. Results: Seven studies for IDE protein level (AD cases = 293; controls = 126), three for mRNA level (AD cases = 138; controls = 81), and three for enzyme activity (AD cases = 123; controls = 75) were pooling together. The IDE protein level was significantly lower in AD cases than in controls (SMD = - 0.47, 95% CI [-0.69, -0.24], p < 0.001), but IDE mRNA and enzyme activity had no significant difference (SMD = 0.02, 95% CI [-0.40, 0.43] and SMD = 0.06, 95% CI [-0.41, 0.53] respectively). Subgroup analyses found that IDE protein level was decreased in both cortex and hippocampus of AD cases (SMD = -0.43, 95% CI [-0.71, -0.16], p = 0.002 and SMD = -0.53, 95% CI [-0.91, -0.15], p = 0.006 respectively). However, IDE mRNA was higher in cortex of AD cases (SMD = 0.71, 95% CI [0.14, 1.29], p = 0.01), not in hippocampus (SMD = -0.26, 95% CI [-0.58, 0.06]). Conclusions: Our results indicate that AD patients may have lower IDE protease level. Further relevant studies are still needed to verify whether IDE is one of the factors affecting Aβ abnormal accumulation and throw new insights for AD detection or therapy.


2016 ◽  
Vol 13 (4) ◽  
pp. 318-320 ◽  
Author(s):  
Teng Jiang ◽  
Jian-Kang Hou ◽  
Qing Gao ◽  
Jin-Tai Yu ◽  
Jun-Shan Zhou ◽  
...  

Author(s):  
Eva Mezeiova ◽  
Martina Hrabinova ◽  
Vendula Hepnarova ◽  
Daniel Jun ◽  
Jana Janockova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document